The startup develops a biopharmaceutical platform that utilizes proprietary peptides to provide anti-inflammatory and antibacterial treatments for wound care and topical applications. This technology addresses the need for effective therapies in a market increasingly challenged by multi-drug resistant infections.
Funding
$12.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic wounds and inflammatory skin conditions are often complicated by excessive inflammation and infection, especially with the rise of multi-drug resistant bacteria. Current treatments may not effectively modulate the immune response or prevent infection, leading to delayed healing and increased patient morbidity.
Solution
Xinnate is developing pharmaceutical therapies based on immune-modulating peptides to address dysfunctional healing by controlling the interplay of inflammatory responses and the presence of microbes. Their primary drug candidate, TCP-25 Gel, utilizes a proprietary peptide that modulates inflammation, maintains an optimal balance between healthy levels and mitigating excessive harmful inflammation, and is effective against both gram-positive and gram-negative bacteria, including antibiotic-resistant strains, while preserving the commensal flora. TCP-25 also reduces wound exudation, improving the wound environment and healing. The company is conducting clinical trials for TCP-25 Gel, including a Phase 2 study in Epidermolysis Bullosa (EB) patients, with plans to expand its portfolio of applications through partnerships with larger pharmaceutical companies.
Target Audience
The primary target audience includes patients with chronic wounds, inflammatory skin conditions, and rare diseases such as Epidermolysis Bullosa (EB), as well as pharmaceutical companies seeking to expand their portfolios with novel wound care and anti-inflammatory treatments.
Features
- TCP-25 peptide modulates inflammation, balancing healthy levels and mitigating excessive harmful inflammation.
- TCP-25 is effective against both gram-positive and gram-negative bacteria, including antibiotic-resistant strains.
- TCP-25 preserves the commensal flora.
- TCP-25 reduces wound exudation, improving the wound environment and healing.
- Proprietary gel formulation preserves the multimodal action of TCP-25.
- Demonstrated safety and preliminary efficacy in a completed Phase 1 study.
- Protected by several international patents.